Sign In
Buy AMRN
$14.53
+0.0600 (+0.415%)
At Close: Jun 03, 2026
Amarin Could Be A Value Pick With An EMA Approval Coming
02:17pm, Tuesday, 02'nd Feb 2021
It's been a long and painful path to market success for Amarin. Legal roadblocks devastated the share price and brought generics to market much sooner than expected.
Why Amarin Corporation Shot 7.7% Higher Today
06:25pm, Monday, 01'st Feb 2021
It's all about the incentives.
Amarin Receives Positive CHMP Opinion for Icosapent Ethyl for Cardiovascular Risk Reduction
12:52pm, Friday, 29'th Jan 2021
Positive opinion is based on extensive clinical study results, including results of the REDUCE-IT® cardiovascular outcomes study
Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit to Include Health Care Insurance Provider
07:35pm, Monday, 25'th Jan 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today an expansion of the scope of its VASCEPA® (icosapent ethyl) cardiovascul
3 Stocks Wall Street Thinks Will Soar 50% or More in 2021
06:08am, Sunday, 24'th Jan 2021
These stocks have one obvious thing in common.
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases
04:30pm, Thursday, 21'st Jan 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent ethyl
Wall Street Was Busy Selling These 2 Stocks in 2020
06:45am, Saturday, 16'th Jan 2021
Investors holding shares in these two companies need to practice patience.
Amarin Corporation PLC (AMRN) CEO John Thero Presents at the 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
08:20pm, Tuesday, 12'th Jan 2021
Amarin Corporation PLC (AMRN) CEO John Thero Presents at the 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
Matinas: Learning From Amarin's Mistakes
08:05pm, Wednesday, 06'th Jan 2021
Matinas: Learning From Amarin's Mistakes
This Stock Could Be a Surprise Growth Pick for 2021
09:32am, Tuesday, 05'th Jan 2021
Down 77% in 2020, Amarin's stock should zoom higher once Vascepa obtains European approval.
Amarin to Present at 39th Annual J.P. Morgan Healthcare Conference
06:05am, Monday, 04'th Jan 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is sch
Amarin (AMRN) Surges: Stock Moves 9% Higher
09:47am, Thursday, 31'st Dec 2020
Amarin (AMRN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
The 10 Worst Performing Stocks of 2020
07:30am, Tuesday, 29'th Dec 2020
These companies are eager to say good riddance to the year that was.
With Alexion Off the Board, Amarin and Biomarin Are Attractive Acquisition Targets
12:38pm, Thursday, 24'th Dec 2020
Biopharma deal-making is expected to pick up in 2021 after its slump in 2020, with a good example being AstraZeneca's (AZN) nearly $40 billion purchase of Alexion Pharmaceuticals (ALXN), which was ann
REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers
